Sepsis (severe) - drotrecogin (withdrawn) (TA84)
Drotrecogin alfa (activated) is recommended for adult patients who
- have severe sepsis that has resulted in multiple organ failure (two or more major organs are not working properly) and
- are being given the most appropriate intensive care support for their condition.
The use of drotrecogin alfa (activated) should be started and supervised by a specialist consultant with skills in intensive care and experience in the care of patients with sepsis.
Drotrecogin alpha (activated) for severe sepsis: withdrawal of product following recent clinical trial results
On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris(R) [drotrecogin alfa (activated)] product in all markets following results of the PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying health care professionals and clinical trial investigators.
As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alpha (activated) for severe sepsis.
- None found
This page was last updated: 10 November 2011
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.